January 3, 2019 / 12:28 PM / in 17 days

BRIEF-Seres Therapeutics Announces Initiation Of Ser-287 Phase 2B Eco-Reset Clinical Study For Ulcerative Colitis

Jan 3 (Reuters) - Seres Therapeutics Inc:

* SERES THERAPEUTICS ANNOUNCES INITIATION OF SER-287 PHASE 2B ECO-RESET CLINICAL STUDY FOR ULCERATIVE COLITIS

* SERES THERAPEUTICS INC - COMPANY HAS RECEIVED $40 MILLION IN MILESTONE PAYMENTS WITH PHASE 2B STUDY START

* SERES THERAPEUTICS - PHASE 2B STUDY IS 3-ARM PLACEBO-CONTROLLED TRIAL OF APPROXIMATELY 200 PATIENTS WITH ACTIVE MILD-TO-MODERATE ULCERATIVE COLITIS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below